Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Debt: 2010-2024

Historic Non-Current Debt for Madrigal Pharmaceuticals (MDGL) over the last 8 years, with Dec 2024 value amounting to $117.6 million.

  • Madrigal Pharmaceuticals' Non-Current Debt rose 190.17% to $339.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.8 million, marking a year-over-year increase of 190.17%. This contributed to the annual value of $117.6 million for FY2024, which is 1.81% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Non-Current Debt stood at $117.6 million for FY2024, which was up 1.81% from $115.5 million recorded in FY2023.
  • Madrigal Pharmaceuticals' 5-year Non-Current Debt high stood at $117.6 million for FY2024, and its period low was $49.3 million during FY2022.
  • For the 3-year period, Madrigal Pharmaceuticals' Non-Current Debt averaged around $94.1 million, with its median value being $115.5 million (2023).
  • Data for Madrigal Pharmaceuticals' Non-Current Debt shows a peak YoY skyrocketed of 134.29% (in 2023) over the last 5 years.
  • Over the past 3 years, Madrigal Pharmaceuticals' Non-Current Debt (Yearly) stood at $49.3 million in 2022, then surged by 134.29% to $115.5 million in 2023, then grew by 1.81% to $117.6 million in 2024.